26,765 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Woodline Partners LP

Woodline Partners LP bought a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 26,765 shares of the biopharmaceutical company's stock, valued at approximately $491,000.

Several other institutional investors also recently bought and sold shares of ACAD. Barclays PLC boosted its stake in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock valued at $4,269,000 after acquiring an additional 154,854 shares in the last quarter. KBC Group NV raised its holdings in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 2,044 shares during the last quarter. R Squared Ltd purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth $47,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of ACADIA Pharmaceuticals by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 35,281 shares of the biopharmaceutical company's stock worth $647,000 after buying an additional 3,378 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 10.9% in the fourth quarter. Principal Financial Group Inc. now owns 143,694 shares of the biopharmaceutical company's stock worth $2,637,000 after buying an additional 14,143 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ACAD shares. Oppenheimer reaffirmed a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, May 16th. Morgan Stanley set a $24.00 price target on shares of ACADIA Pharmaceuticals and gave the stock an "equal weight" rating in a report on Tuesday, May 20th. Deutsche Bank Aktiengesellschaft raised shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and raised their price target for the stock from $20.00 to $35.00 in a report on Wednesday, May 21st. HC Wainwright raised their price target on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the stock a "buy" rating in a report on Monday, May 19th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $26.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, May 19th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.83.

Insider Activity at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the sale, the executive vice president now owns 56,889 shares in the company, valued at approximately $969,957.45. This trade represents a 5.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,746 shares of company stock worth $428,221. 28.30% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Price Performance

ACAD stock traded down $0.69 during midday trading on Friday, hitting $21.60. 1,446,509 shares of the stock traded hands, compared to its average volume of 1,939,166. The firm has a market cap of $3.62 billion, a P/E ratio of 27.69 and a beta of 0.47. The stock's fifty day simple moving average is $16.87 and its 200-day simple moving average is $17.48. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $244.32 million for the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm's revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. On average, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.